Exact Mass: 407.2209
Exact Mass Matches: 407.2209
Found 33 metabolites which its exact mass value is equals to given mass value 407.2209,
within given mass tolerance error 4.0E-5 dalton. Try search metabolite list with more accurate mass tolerance error
8.0E-6 dalton.
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
2-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline-1,3-dione
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists ARC 239 is an α2B/C-adrenergic receptor antagonist with pKi of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a Ki of 63.1 nM[1][2].
(3Z,6S)-3-{{2-(1,1-dimethylprop-2-en-1-yl)-7-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-1H-indol-3-yl}methylidene}-6-methylpiperazine-2,5-dione|variecolorin M
(3Z,6S)-3-{{2-(1,1-dimethylprop-2-en-1-yl)-7-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-1H-indol-3-yl}methylidene}-6-methylpiperazine-2,5-dione|variecolorin M
(3S,6S)-3-((1,7-dihydro-7,7-dimethyl-2-(2-methylbut-3-en-2-yl)pyrano[2,3-g]indol-3-yl)methyl)-6-methylpiperazine-2,5-dione|talathermophilin D
(3S,6S)-3-((1,7-dihydro-7,7-dimethyl-2-(2-methylbut-3-en-2-yl)pyrano[2,3-g]indol-3-yl)methyl)-6-methylpiperazine-2,5-dione|talathermophilin D
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide
ethyl 4-(2,5-dimethylphenyl)-6-[[(4-methylphenyl)methylamino]methyl]-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
ethyl 4-(2,5-dimethylphenyl)-6-[[(4-methylphenyl)methylamino]methyl]-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-phenylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-phenylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
[(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
[(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(1S)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1S)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
[(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylphenyl)phenyl]-2-oxo-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylphenyl)phenyl]-2-oxo-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists ARC 239 is an α2B/C-adrenergic receptor antagonist with pKi of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a Ki of 63.1 nM[1][2].
(3s,6s)-3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
(3s,6s)-3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
5-hydroxy-3-{[7-(4-hydroxy-3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
5-hydroxy-3-{[7-(4-hydroxy-3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
(1r,10s,11r,12s,22r)-16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
(1r,10s,11r,12s,22r)-16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
n-[3-(n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido)propyl]benzenecarboximidic acid
n-[3-(n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido)propyl]benzenecarboximidic acid
(3z,6s)-3-({5-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z,6s)-3-({5-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
(3z,6s)-3-({7-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z,6s)-3-({7-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
5-hydroxy-6-methyl-3-{[5-(3-methyl-2-oxobutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
5-hydroxy-6-methyl-3-{[5-(3-methyl-2-oxobutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
1-(3-{[(2z,5s)-3,6-dihydroxy-5-methyl-5h-pyrazin-2-ylidene]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-5-yl)-3-methylbutan-2-one
1-(3-{[(2z,5s)-3,6-dihydroxy-5-methyl-5h-pyrazin-2-ylidene]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-5-yl)-3-methylbutan-2-one
(3z)-3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z)-3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
5-hydroxy-3-{[5-(2-hydroxy-3-methylbut-3-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
5-hydroxy-3-{[5-(2-hydroxy-3-methylbut-3-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
n-{3-[(2e)-n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido]propyl}benzenecarboximidic acid
n-{3-[(2e)-n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido]propyl}benzenecarboximidic acid
